FDA Approves Johnson & Johnson’s Oral Pill for Psoriasis, Company Says

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

'Potential Game Changer' for Psoriasis Gets Green Light From FDA

(MedPage Today) -- The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children 12 or older with moderate...

J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug, Icotyde, has the potential to top $5 billion in sales.

FDA approves Johnson & Johnson’s oral pill for psoriasis, company says

The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 years and older.

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

J&J wins approval for first-of-its-kind psoriasis pill

The FDA approval of Icotyde, a daily treatment, could roil a multibillion-dollar market, including AbbVie’s Skyrizi and J&J’s own Tremfya.